New FDA Drug Approvals in 2026: The Full List (Updated July 2026)

2026 has been a genuinely consequential year at the FDA — and not just because of volume. Roughly 22 novel drugs cleared review in the first half of the year, but the ones that will actually change day-to-day routines are concentrated in metabolic health: for the first time, the two most-prescribed weight-management molecules are available as pills, and the regulatory ground under compounded GLP-1s has shifted.

Below is the full list of 2026 FDA approvals to date, followed by a closer look at the ones that matter if you track a metabolic or peptide protocol — plus an honest status check on the two compounds this community asks about most, CagriSema and retatrutide.

Every 2026 FDA novel drug approval so far

"Novel" approvals are new molecular entities and new therapeutic biologics that had never been approved in the U.S. before — the FDA’s own headline measure of innovation. Here is the 2026 run, in order.

One more approval belongs in any 2026 conversation even though it landed days earlier: the Wegovy pill (oral semaglutide 25 mg) was approved December 22, 2025 and launched in the U.S. in early January 2026. Functionally, it is a 2026 arrival.

Foundayo (orforglipron): the first small-molecule GLP-1

Approved April 1, 2026, Eli Lilly’s Foundayo (orforglipron) is the headline approval of the year for metabolic health. Every GLP-1 receptor agonist before it — semaglutide, tirzepatide, liraglutide — is a peptide. Orforglipron is not: it is a small molecule, which is why it survives the gut without the absorption enhancer and rigid dosing ritual that oral semaglutide requires.

The practical consequence is the marketing line, and it is a real one: any time of day, with or without food or water restrictions. Oral semaglutide must be taken on an empty stomach with a small sip of water, followed by a 30-minute wait before eating, drinking, or taking anything else. Orforglipron drops that requirement entirely.

What the trials showed

Approval rested on the Phase 3 ATTAIN-1 and ATTAIN-2 trials. In ATTAIN-1, participants on the highest dose who stayed on treatment lost an average of 27.3 lb (12.4% of body weight), versus 2.2 lb (0.9%) on placebo.

That is meaningfully below injectable tirzepatide territory and below oral semaglutide’s OASIS 4 result — a trade of peak efficacy for convenience and, likely, supply. Small molecules are far cheaper to manufacture at scale than peptides, which is the quiet story behind the pricing: eligible Medicare Part D patients were slated to access it for about $50 per month starting July 1, 2026.

It carries the class boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, and is contraindicated in anyone with a personal or family history of MTC or MEN 2.

The Wegovy pill (oral semaglutide 25 mg)

Approved December 22, 2025 and on U.S. shelves from early January 2026, the Wegovy pill was the first oral GLP-1 approved for weight management. In the OASIS 4 trial, once-daily oral semaglutide 25 mg produced 16.6% mean weight loss among participants who adhered to treatment, with roughly one in three losing 20% or more — essentially matching injectable Wegovy 2.4 mg.

The catch is the ritual. Fasted dosing, plain water only, 30-minute wait. Adherence is not a footnote with this drug; it is the mechanism. Which is exactly why logging every dose — and specifically whether each one was taken correctly — matters more with an oral GLP-1 than with a weekly injection.

The peptide approvals of 2026

Two 2026 approvals are genuine peptide therapeutics — worth knowing precisely because they show what the approved end of the peptide spectrum looks like.

Yuviwel (navepegritide) — February 27, 2026

A once-weekly subcutaneous C-type natriuretic peptide (CNP) analog from Ascendis Pharma, granted accelerated approval to increase linear growth in children aged 2 and older with achondroplasia and open epiphyses. It works by counteracting the overactive FGFR3 signaling that constrains bone growth. In the Phase 3 ApproaCH trial, annualized growth velocity was 5.9 cm/year versus 4.4 cm/year on placebo.

Hepcludex (bulevirtide-gmod) — May 22, 2026

A lipopeptide entry inhibitor and the first treatment the FDA has ever approved for chronic hepatitis delta virus infection — the most severe form of viral hepatitis. Long available in Europe, its accelerated U.S. approval closes a decades-old treatment gap.

The regulatory shift that affects the most people: compounded GLP-1s

No approval in 2026 will touch as many people as a rulemaking that is not an approval at all. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — concluding there is no clinical need for outsourcing facilities to compound them from bulk drug substance.

The context: the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. With no shortage and no place on the bulks list, the legal footing for large-scale compounded GLP-1s largely disappears. The comment period was extended to July 30, 2026, so no final determination has been published yet.

Worth separating from the other compounding story running the same week: on July 23–24 an FDA advisory panel voted in favor of adding BPC-157, TB-500 and five more peptides to the 503A bulks list — a different list, a different facility type, and moving in the opposite direction.

If it is finalized, mass-scale compounding of these three molecules by outsourcing facilities would be permanently off the table. Anyone currently on a compounded GLP-1 has a straightforward reason to keep a clean, dated record of dose, source, and response — because a switch to a branded product is a protocol change worth measuring against a documented baseline, not a vague memory.

What is still pending: CagriSema and retatrutide

CagriSema — filed, under review

Novo Nordisk submitted the NDA for CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) on December 18, 2025, with FDA review running through 2026. It would be the first once-weekly GLP-1 + amylin analogue combination approved for weight management. In the pivotal REDEFINE 1 trial it produced roughly 22.7% mean weight loss at 68 weeks, with 91.9% of participants losing at least 5% of body weight versus 31.5% on placebo. See our CagriSema overview for how the two components differ.

Retatrutide — still Phase 3

Retatrutide is not FDA approved, and as of July 2026 no NDA filing or decision date has been announced. The triple GLP-1/GIP/glucagon agonist has posted the strongest weight-loss numbers of any investigational obesity drug in Phase 3 TRIUMPH readouts, with further trials reporting through 2026 — but strong data is not approval. Realistically, an approval is a 2027-or-later question.

That distinction matters. Anything sold as retatrutide today is unapproved material outside the regulated supply chain, with no assurance of identity, purity, or concentration. Our retatrutide library entry covers what the compound is; it does not endorse using it.

What these approvals change about tracking

Two approvals in seven months moved GLP-1 therapy from a weekly injection to a daily pill — and daily oral dosing breaks most of the habits built around weekly protocols.

• Frequency changes everything. A weekly injection is a calendar event you remember. A daily pill is a habit you forget. Missed-dose patterns only show up if something is counting.
• Adherence quality is now a data point. With oral semaglutide, "took it" and "took it correctly" are different outcomes. Log the conditions, not just the dose.
• Switching creates a before/after. Injectable to oral, compounded to branded, semaglutide to orforglipron — every switch is only interpretable against a documented baseline of weight, side effects, and energy.
• Side-effect timing shifts. GI effects that clustered around one injection day now spread across every day. A journal makes that pattern visible in weeks instead of months.
• Titration schedules multiply. Both oral agents step up in dose over time. Knowing exactly which week you are in — and what happened at the last step — is the whole game.

The bottom line

2026’s approval list is broad — hepatitis delta, thyroid eye disease, IgA nephropathy, a first-in-class hypertension drug — but its center of gravity is metabolic. Foundayo proved a small molecule can do GLP-1 work in pill form, the Wegovy pill proved a peptide can too if you follow the rules, and the 503B proposal is quietly steering people off compounded sources and onto approved ones.

For anyone running a protocol through this, the practical takeaway is unglamorous: more options and more switching means more variables, and variables you do not record are variables you cannot learn from. We will update this page as the rest of 2026 lands.

Frequently asked questions